The Online Investor
ViroPharma Inc. (VPHM)

ViroPharma is a biotechnology company. Co. markets and sells Cinryze in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Co. also sells branded and authorized generic Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is indicated for the treatment of C. difficile-associated diarrhea (CDAD). Co.'s product development portfolio is primarily focused on these programs: C1 esterase inhibitor [human]; maribavir for cytomegalovirus infection; VP20621 for prevention of recurrent CDAD; and VP20629 for treatment of Friedreich's Ataxia.
Company Name: 
ViroPharma Inc.
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree VPHM Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.55 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

ViroPharma Inc. (VPHM) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.